Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia

Matthieu F. Bastide1,2, Christelle Glangetas1,2, Evelyne Doudnikoff1,2, Qin Li3,4, Mathieu Bourdenx1,2, Pierre-Olivier Fernagut1,2, Éric C. Dumont5, François Georges1,2 & Erwan Bézard1,2,3,4

A whole brain immediate early gene mapping highlighted the dorsolateral bed nucleus of the stria terminalis (dlBST) as a structure putatively involved in L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesia (LID), the debilitating side-effects of chronic dopamine replacement therapy in Parkinson's disease (PD). dlBST indeed displayed an overexpression of ΔFosB, ARC, Zif268 and FRA2 only in dyskinetic rats. We thus hypothesized that dlBST could play a role in LID hyperkinetic manifestations. To assess the causal role of the dlBST in LID, we used Daun02 inactivation to selectively inhibit the electrical activity of dlBST ΔFosB-expressing neurons. Daun02 is a prodrug converted into Daunorubicin by β-galactosidase. Then, the newly synthesized Daunorubicin is an inhibitor of neuronal excitability. Therefore, following induction of abnormal involuntary movements (AIMs), 6-OHDA rats were injected with Daun02 in the dlBST previously expressing β-galactosidase under control of the FosB/ΔFosB promoter. Three days after Daun02 administration, the rats were tested daily with L-Dopa to assess LID. Pharmacogenetic inactivation of ΔFosB-expressing neuron electrophysiological activity significantly reduced AIM severity. The present study highlights the role of dlBST in the rodent analog of LID, offering a new target to investigate LID pathophysiology.

The gold standard treatment for Parkinson’s disease (PD) remains the dopamine precursor L-3,4-dihydroxyphenylalanine (L-Dopa). Long-term L-Dopa treatment systematically leads to abnormal involuntary movements (AIMs) called L-Dopa-induced dyskinesia (LID)1. From the 90s to nowadays, growing evidence suggest that the mechanisms underlying PD and LID pathophysiology involve not only motor regions but also associative and limbic domains of the basal ganglia and beyond1–4, notably the bed nucleus of the stria terminalis (BST)2 (Fig. 1A).

Recently, a whole brain search approach highlighted the dorsolateral (dl) BST, which displayed an overexpression of 4 independent immediate early genes (IEG): ΔFosB, ARC, Zif268 and FRA2 only in dyskinetic 6-OHDA-lesioned rats. The dlBST is composed of 2 nuclei, the oval (ovBST) and juxta (jxBST), both of which showed a significant correlation between ΔFosB or FRA2 expression and LID severity5. Based on this evidence, we hypothesize that the dlBST could be actively involved in LID manifestations.

Interestingly, striatal down-regulation of FosB expression or electrical inhibition of FosB/ΔFosB-expressing neurons decreased LID severity both in rats and non-human primates6–8, demonstrating that FosB/ΔFosB is not only a marker of LID but that inhibiting its expression or the electrical activity of the neurons expressing it functionally impact AIMs or LID. Moreover, similar results were recently obtained following inactivation of FosB/ΔFosB-expressing neurons in a structure located outside of the basal ganglia (e.g. the lateral habenula) highlighting the involvement of extra-basal ganglia nuclei in LID manifestations9.

Therefore, to assess the role of the dlBST in LID pathophysiology, we used the FosB promoter to selectively drive the expression of β-galactosidase in FosB/ΔFosB-expressing neurons. Then, we assessed the role of these neurons.

1Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France. 2CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000, Bordeaux, France. 3Motac neuroscience Ltd, Manchester, UK. 4Institute of Lab Animal Sciences, China Academy of Medical Sciences, Beijing, China. 5Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada. Matthieu F. Bastide and Christelle Glangetas contributed equally to this work. François Georges and Erwan Bézard jointly supervised this work.

Correspondence and requests for materials should be addressed to E.B. (email: erwan.bezard@u-bordeaux.fr)

Received: 11 January 2017
Accepted: 12 April 2017
Published online: 24 May 2017
ΔFosB-expressing dlBST neurons in the rat model of LID in PD8–11 by inhibiting their electrical activity with the Daun02-inactivation method8, 9, 12–15.

Results
LID induce D1R expression in the dlBST. Consistent with previous observations in the basal ganglia, we also found an increased expression of the dopaminergic D1 receptor (D1R) protein in the dlBST of dyskinetic rats (Fig. 1C), which co-localized with ΔFosB (Fig. 1D).

Pharmacogenetic inhibition of dlBST ΔFosB-expressing neurons activity alleviated AIMs. To directly assess a causal role of dlBST in AIM severity in the rodent analogue of dyskinesia, we inhibited the electrical activity of dlBST ΔFosB-expressing neurons using the selective Daun02/ß-galactosidase inactivation method. The prodrug Daun02 was locally administrated and presumably converted into Daunorubicin by ß-galactosidase, readily produced in neurons expressing the E. coli LacZ gene under the FosB/ΔFosB gene promoter8, 9, 12–14. Then, the newly synthesized Daunorubicin is a potent inhibitor of neuronal excitability by reducing calcium ion-dependent action potentials15.

We recently showed that Daun02/ß-galactosidase inactivation (genetic manipulation) or Daunorubicin injection (pharmacological manipulation) inhibit striatal neurons’ activity both in vitro and ex vivo8. Using in vivo single-unit extracellular recordings, we demonstrate that intra-dlBST injection of Daunorubicin (Fig. 2A,B) induced a 60% decrease in the number of evoked spikes in response to insular Ctx stimulation (Fig. 2C,D, Percentage of change between before and after values in Rmag: PBS = 101.3 ± 3.36%, n = 7 cells; Daunorubicin 4 µM = 42.20 ± 8.8%, n = 4 cells; Daunorubicin 8 µM = 41.85 ± 10.03%, n = 6 cells. One way Anova followed
Figure 2. Daun02-induced inactivation of ΔFosB-expressing dlBST neurons alleviates LID in rats. (A) INS Ctx stimulation and ov/jxBST recording protocols. (B) Histological controls of stimulation site (stim: INS Ctx), recording site (rec: ov/jx BST; red fluorescent spot), injection site (green fluorescent labeling) (scale bar 1 mm) with 2 representative insets indicating the respective sites with white arrows (scale bar 0.6 mm). (C) Quantitative analysis of inhibitions induced by Daunorubicin infusion (Daunorubicin 4: 4 µg/µL; Daunorubicin 8: 8 µg/µL) on excitatory responses evoked by the INS Ctx stimulation. Only neurons responding to Daunorubicin have been included in this analysis (4 out of 7 for Daunorubicin 4 and 6 out of 6 for Daunorubicin 8) (** *p < 0.001 from PBS). (D) Typical PSTHs and associated rasters showing responses of ov/jx BST neurons before and after daunorubicin (4 µg/µL) infusion. Stimulus at t0 (gray line). Bin width, 5 ms. Representative electrophysiological trace in inset. (E) Cumulated axial, limb and orolingual (A.L.O.) AIMs scores in L-Dopa-treated 6-OHDA rats (n = 10) before and after Daun02 and after control solution injection (median ± range; *p < 0.05 from baseline and $p < 0.05 from control solution). (F) Cumulated rotation scores in L-Dopa-treated 6-OHDA rats (n = 10) before and after Daun02 and after control solution injection (median ± range). (G) Representative dlBST cytochemical detection of β-galactosidase expression in the Daun02-injected side of dyskinetic rats (scale bar: 300 µm) with an inset (scale bar: 20 µm).
by a bonferroni post hoc: F_{(2,14)} = 22.88, p < 0.0001). No change was observed on basal spontaneous activity after intra-dlBST injection of PBS or Daunorubicin (PBS: before = 0.42 Hz ± 0.27 Hz, after = 0.17 Hz ± 0.12 Hz, N = 6 neurons, paired t test; p = 0.1663; Daunorubicin 4 µM: before = 2.08 Hz ± 1.99 Hz, after = 2.29 Hz ± 2.2 Hz, N = 4 neurons, paired t test; p = 0.4; Daunorubicin 8 µM: before = 0.34 Hz ± 0.15 Hz, after: 0.53 Hz ± 0.39 Hz, N = 4 neurons, paired t test; p = 0.53). All together, these results demonstrate that intra-dlBST injection of Daunorubicin target the synaptic activity by decreasing the excitability of dlBST neurons (decrease in the number of evoked spikes during each train of stimulation of the INS Ctx) without affecting their basal activity.

Therefore, we injected, in vivo, a FosB-LacZ lentivirus expressing the β-galactosidase only in the dlBST and of 6-OHDA-lesioned rats chronically treated with L-Dopa. Due to the small size of the dlBST and the adjoining internal capsule, all viral infusions were performed under in vivo electrophysiological guidance using small volume of virus solution (250 nl) to limit virus particles diffusion to adjacent fiber bundles. After the establishment of stable AIMs, a single intra-dlBST administration of Daun02 significantly decreased AIMs compared to baseline score (*p < 0.05; Fig. 2E). AIMs reduction lasted 3 days compared with baseline scores (22%, 21% and 13% respectively; *p < 0.05 for all, Fig. 2E) in keeping with previous demonstration of Daun02-mediated behavioural span. After a return to baseline AIMs scores, a control solution, (vehicle without Daun02), was injected in the dlBST of the same rats. AIMs scores were unaffected in vehicle-treated rats whereas Daun02-inactivation significantly decreased AIMs scores compared to vehicle for 2 days (19% and 18% respectively; *p < 0.05 for all; Fig. 2E). Daun02-inactivation did not affect the rotational behavior, an index of the anti-parkinsonian effect of L-Dopa, compared with both baseline and control-treated rats (Fig. 2F). β-galactosidase staining confirmed an expression of the FosB-LacZ lentivirus restricted to the dlBST region (Fig. 2G).

**Discussion**

More than fifty years after its introduction in clinical therapy, L-Dopa remains the gold standard treatment for PD but rapidly induces fluctuations and LID. Those latter have been associated with both presynaptic and postsynaptic striatal mechanisms although extra-striatal consequences are very likely, especially in DA-rich brain regions. In the present study, we unravelled the involvement of an extra-basal ganglia brain region, the dlBST, in LID pathophysiology. First, we demonstrated that the electrical inhibition of FosB dlBST neurons decreased LID severity in the rat model of L-DOPA-induced dyskinesia. Altogether, these results demonstrate, for the first time, a translational validation of the functional involvement of the dlBST in LID, supporting the role of structures outside of the basal ganglia in LID pathophysiology as already suggested by a recent study.

The study is not however without limitations. Experiments were performed in the dyskinetic unilateral 6-OHDA-lesioned rat, which, although it has demonstrated its translational and heuristic values, bears the paradoxical drawback of displaying accurate and reproducible extent and pattern of lesion, at odds with the clinical situation. Thus the modest, though significant, decrease in AIMs after pharmacogenetic inhibition of dlBST in this model calls for caution in hoping to translate this finding in human. Until now, only large reversal of AIM severity has indeed translated into 25–40% reduction of LID in PD patients. In other words, modulation of dlBST activity is unlikely to offer a new target to innovative treatments of LID despite its pathophysiological interest.

The dlBST is a small structure requiring special care when injecting the viral vector. The viral infusions were thus performed under in vivo electrophysiological guidance using small volume of virus solution (250 nl) to limit virus particles diffusion to adjacent fiber bundles. That the dlBST is located next to the internal capsule is actually a barrier preventing diffusion, of either the viral vector when injecting it or of daunorubicin itself. We demonstrated that targeting small neuronal ensembles distant from the striatum (e.g. Lateral Habenula) can significantly reduce dyskinesia severity. We found no evidence demonstrating that daunorubicin can be secreted by neurons and then taken up by neighboring passing fibers. However, the following intrastratial injection of daun02 would result in a pyramidalotome-like effect (e.g. ipsilateral motor deficit). We however previously demonstrated that intrastratial administration of daun02 alleviates LID and found no evidence for a deleterious effect of daun02 on motor behavior.

The BST receives robust monoaminergic inputs featuring serotonin (5-HT), noradrenaline (NA) and dopamine. The dlBST dopamine inputs originate in the ventral tegmental area (VTA), the periaqueducal gray region and the retrorubral field. They form a fairly dense input to the dlBST with dense dopamine terminal fields in the ovBST and the jxBST. In addition, the dlBST integrates strong inputs from the central amygdala and insular cortex to modulate motivation and negative emotional states and adjust information on motor and anxiety-related function via projections to the substantia nigra pars compacta and basolateral amygdala. This anatomical organization has been confirmed in primate and suggests that the dlBST is in a prominent position to modulate dopaminergic circuits involved in initiating movement. Interestingly, previous studies demonstrated that the monoaminergic neurochemistry of the amygdala and cortical areas and IEG-expression pattern are altered in animal models of PD and LID. Consistent with clinical observations, these results suggest that networks involved in affective, anxiety-related and motivational processes, could also impact LID severity either directly or indirectly. Here, we provided behavioral evidences that inactivation of FosB/AFosB dlBST neurons decreased LID severity. Reduction of anxiety levels has been shown to participate to the reduction of LID severity. Anxiety-related emotional states are controlled by multiple neuronal circuits that share robust and reciprocal connections with the dlBST. In particular, the dlBST tunes anxiety-related function via monosynaptic projections to the basolateral amygdala. In addition to emotional functions processing, the basolateral amygdala also modulates sensorimotor information processing and therefore participate to reduction of AIM severity.

Together with the recent demonstration that neurons in the lateral habenula contribute to the expression of LID, the present study further highlight the cognitive contribution to the expression of abnormal involuntary...
movements triggered by L-Dopa and identifies some of the underlying networks and mechanisms as shown with the involvement of the dlBST and increased D1R expression.

D1R signaling is enhanced in LID. D1R in LID has been described both as sensitized (increased agonist affinity or increased coupling to Gs/olf per unit time)\(^1\)\(^,\)\(^2\)\(^,\)\(^3\)\(^,\)\(^4\)\(^,\)\(^5\) and as kept in an active conformation at membrane for a longer duration\(^6\)\(^,\)\(^7\)\(^,\)\(^8\)\(^,\)\(^9\). Consequently (or in parallel), LID disturbs striatal D1R signalling pathways\(^10\)\(^,\)\(^11\)\(^,\)\(^12\)\(^,\)\(^13\)\(^,\)\(^14\)\(^,\)\(^15\) inducing, among others, alterations in IEG expression, especially for \(\Delta FosB\)\(^\text{35}\), which impacts LID severity\(^5\)\(^,\)\(^6\)\(^,\)\(^7\)\(^,\)\(^8\)\(^,\)\(^9\)\(^,\)\(^10\). Interestingly, the dlBST shares similar consequences of the chronic L-DOPA treatment with the striatum, with an increase in D1R expression induced exclusively by a dyskinesiogenic chronic L-DOPA treatment, which co-localized with \(\Delta FosB\).

In conclusion, the present study describes the involvement of an hitherto unnoticed extra-basal ganglia structure, the dlBST, in LID pathophysiology. Taken together, our results highlight for the first time the functional role of the dlBST in LID.

Material and Methods

Study approval. Experiments were performed in accordance with the European Union directive of September 22, 2010 (2010/63/EU) on the protection of animals used for scientific purposes. The Institutional Animal Care and Use Committee of Bordeaux (CE50) approved the present experiments under the license numbers 5012099-A.

Daun02/\(\beta\)-galactosidase inactivation method. Rat experiments. Adult male Sprague-Dawley rats (Charles River Laboratories, Lyon, France), weighing 175–200 g at the beginning of the experiment, were used (\(n = 12\)). They were housed under standard laboratory conditions in a 12-hour light/12-hour dark cycle with free access to food and water. On Day 0, unilateral injection of 6-OHDA (2.5 \(\mu\)g at 3 \(\mu\)l/g) was unilaterally injected in the right medial forebrain bundle (AP \(= -3.7 \text{ mm};\) ML \(= +1.6 \text{ mm};\) DV \(= -8 \text{ mm}\) relative to Bregma), in rats treated 30 minutes before with citalopram (1 mg/kg i.p.) and desipramine hydrochloride (20 mg/kg i.p.) according to previously published procedures\(^5\)\(^,\)\(^10\)\(^,\)\(^11\)\(^,\)\(^31\)\(^,\)\(^36\).

At the same time, all the rats were injected with 250 nl of a lentiviral vector expressing LacZ (coding for \(\beta\)-galactosidase) under control of a FosB promoter with a final titer \(5.6/7.2 \times 10^7\) infectious particles/ml, as previously reported\(^6\)\(^,\)\(^9\), in the dlBST (AP \(= -0.4 \text{ mm};\) ML \(= +1.8 \text{ mm};\) DV \(= -5.6/7.2 \text{ mm}\)). All lentiviral injections were done under \textit{in vivo} electrophysiological guidance whereby the dlBST was located upon specific cortical input stimulation\(^37\). Stimulation and recording electrodes were respectively inserted into the insular cortex (INS Ctx; AP \(= -0.2 \text{ mm};\) ML \(= +5.8 \text{ mm};\) DV \(= -4.4 \text{ mm}\)) and the Ov/jxBST (AP \(= -0.4 \text{ mm};\) ML \(= +1.8 \text{ mm};\) DV \(= -5.6/7.2 \text{ mm}\)), respectively. Bipolar electrical stimulation of the INS Ctx was conducted with a concentric electrode (Phymep, Paris) and a stimulus isolator (500 \(\mu\)s, 0.2–2 mA; Digitimer). Baseline was recorded for 10 min (2 \(\times 100 \text{ pulses; } 0.5 \text{ Hz}\)). Ov/jxBST recordings were done using a glass micropipette (tip diameter, 1–2 \(\mu\)m; 10–15 MΩ) filled with a 2% sky blue pontame solution in 0.5 M sodium acetate. Extracellular potentials were recorded with an Axoclamp-2B amplifier and filtered (300 Hz/0.5 KHz). Single neuron spikes were collected online (CED 1401, SPIKE2, Cambridge Electronic Design). During electrical stimulation of the INS Ctx, cumulative peristimulus histograms (PSTHs, 5 ms bin width) of ov/jxBST activity were generated for each recorded neuron. Then, guide cannulas were implanted as previously described\(^6\)\(^,\)\(^9\) \((\text{AP} = -0.4 \text{ mm};\) ML \(= +1.8 \text{ mm};\) DV \(= -5.6/7.2 \text{ mm}\)) and cemented to the skull for subsequent Daun02 injections.

Rats displaying an impaired stepping test\(^5\)\(^,\)\(^10\)\(^,\)\(^31\) assessed on days 18 to 20 were retained for experiments (\(n = 10\)). Lesion extent was also quantified \textit{post-mortem} by the loss of tyrosine hydroxylase-immunopositive fibers in the striatum and animals displaying a loss greater than 95% were considered as lesioned. From day 21 onwards, 10 rats received daily an i.p. injection of a combined dose of benzerazine (15 mg/kg) and L-Dopa (6/10 mg/kg) for 10 days. On the 31\(^{\text{th}}\) day post-6-OHDA and FosB-LacZ lentiviral injections, the baseline abnormal involuntary movements (AIMs) score was assessed. The 4 AIMs categories (limb, axial, orolingual, and locomotive) were scored using a validated rating scale\(^38\)\(^,\)\(^39\) for 1 minute every 30 minutes for 2 hours (total 4 observations; maximal score for each observation, 1–6) performed by a blinded trained investigator as previously described\(^5\)\(^,\)\(^10\)\(^,\)\(^31\)\(^,\)\(^36\). The baseline AIMs scores are 38/48 for the cumulated axial, limb and orolingual AIMs scores and 7/16 for the cumulated rotation scores.

On the 32\(^{\text{nd}}\) day, animals (\(n = 10\)) received a 6 mg/kg L-dopa injection 1 hour before a 500 nl Daun02 injection (4 \(\mu\)g/\(\mu\)l in 5% DMEM, 5% Tween-80 in PBS at 0.5 \(\mu\)l/min)\(^8\)\(^,\)\(^9\) in the dlBST under light isoflurane anesthesia before being placed in their home cage for 3 days as described\(^5\)\(^,\)\(^10\)\(^,\)\(^11\)\(^,\)\(^13\)\(^,\)\(^14\). From the 3\(^{\text{rd}}\) day after Daun02 injection, all rats (\(n = 10\)) received a daily 6 mg/kg L-Dopa injection and AIMs were scored\(^8\)\(^,\)\(^9\). To ensure reversibility of Daun02-induced inactivation, vehicle (5% DMEM, 5% Tween-80 in PBS at 0.5 \(\mu\)l/min) was injected in the same animals 9 days after Daun02 injection and AIMs were evaluated, following the same protocol.

At the end of the Daun02 experiment (day 47, Fig. 1B) and 1 hour after the last L-DOPA injection, i.e. at the peak of behavioural effect, rats were deeply anesthetized with pentobarbital (120 mg/kg, i.p., VWR) and perfused transcardially with 0.9% NaCl followed by ice-cold 4% formaldehyde in PBS. The timeline (Fig. 1B) summarized these 6 weeks of experimental manipulations. Finally, brains were removed, postfixed overnight in the same fixative (4°C), then cryoprotected for 48 h at 4°C in 20% PBS-sucrose. Brains were frozen in isopentane at –45°C and stored at −80°C until sectioning.

\textit{In vivo} electrophysiological validation of the Daunorubicin-induced electrical inhibition in dlBST neurons. Stereotoxic surgery for \textit{in vivo} electrophysiology, stimulation and recording protocols were done as described above and previously\(^37\). Local delivery of Daunorubicin (4 \(\mu\)M and 8 \(\mu\)M) or its vehicle (PBS) was done using double barrel pipettes as previously described\(^37\). Each cell was tested with 100 nL of Daunorubicin or the vehicle. At the end of each recording experiment, the electrode placement was marked with an iontophoretic
deposit of sky blue dye (−20 μA, 15 min). To mark electrical stimulation sites, +50 μA was passed through the stimulation electrode for 90 s. Brains were frozen in isopentane and cut with a cryostat (30 μm thick). Sections were mounted with DAPI vectashield medium and observed with epifluorescent and transmission microscopy.

Cytochemical detection of β-galactosidase. Coronal sections (50 μm) were collected, washed twice in PBS and incubated overnight at 37 °C in freshly prepared staining buffer [1 mg/mL X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside), 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, and 2 mM MgCl2 in PBS, pH 6.0] as previously described. Brain sections were washed with PBS, counterstained with neutral red and examined at ×10 and ×40 magnification. The degree of transduction reached in the dlBST was calculated through previous quantifications made with the same lentiviral vector.

Histological data analysis. Coronal rat brain sections (50 μm) were collected and processed for tyrosine hydroxylase (MAB318, Millipore), ΔFosB (sc-48, Santa-Cruz) and DIR (D2944, Sigma) as previously described.

Data Analysis. Rat behavioural data were analyzed with Wilcoxon signed-rank t-test. All data are presented as mean ± SEM with a threshold for statistical significance at p < 0.05. For in vivo electrophysiological experiments, cumulative PSTHs of ov/jx BST activity were generated during electrical stimulation of the INS Ctx. Excitatory magnitudes (Rmag values) were normalized for different levels of baseline impulse activity. In brief, the mean and SD of counts per bin were determined for a baseline period, defined as the 500 msec epoch preceding stimulation. The onset of excitation was defined as the first of 5 bins for which the mean value exceeded the mean baseline activity by 2SD, and response offset was determined as the time at which activity had returned to be consistently within 2SD of baseline. Rmag values for excitation were calculated according to: Excitation Rmag = (counts in excitatory epoch) − (mean counts per baseline bin X number of excitatory bins in excitation epoch). For a comparison between three groups, values were subjected to a one–way ANOVA followed (if significant) by Bonferroni post hoc tests.

References
1. Bastide, M. F. et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 132, 96–168 (2015).
2. Guigoni, C. et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. The Journal of neuroscience 25, 2102–2107 (2005).
3. Engeln, M., De Deurwaerdere, P., Li, Q., Bezard, E. & Fernagut, P. O. Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cerebral cortex, doi:10.1093/cercor/bhu076 (2014).
4. Bezard, E., Crossman, A. R., Gross, C. E. & Brotchie, J. M. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson’s disease. FASEB journal 15, 1092–1094 (2001).
5. Bastide, M. F. et al. Immediate–early gene expression in structures outside the basal ganglia is associated to L-DOPA-induced dyskinesia. Neurobiology of disease 62, 179–192 (2014).
6. Andersson, M., Hilbertson, A. & Cenci, M. A. Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiology of disease 6, 461–474 (1999).
7. Berton, O. et al. Striatal overexpression of DeltaJunD resists L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biological psychiatry 66, 554–561 (2009).
8. Engeln, M. et al. Selective Inactivation of Striatal FosB/DeltaFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia. Biological psychiatry 79, 354–361 (2016).
9. Bastide, M. F. et al. Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia. Biological psychiatry 79, 345–353 (2016).
10. Porras, G. et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. The Journal of clinical investigation 122, 3977–3989 (2012).
11. Ahmed, M. R. et al. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson’s disease. Sci Transl Med 2, 28ra28 (2010).
12. Fanous, S. et al. Role of orbitofrontal cortex neuronal ensembles in the expression of incubation of heroin craving. The Journal of neuroscience 32, 11600–11609 (2012).
13. Bossert, J. M. et al. Ventral medial prefrontal cortex neuronal ensembles mediate context–induced relapse to heroin. Nature neuroscience 14, 420–422 (2011).
14. Koya, E. et al. Targeted disruption of cocaine-activated nucleus accumbens neurons prevents context-specific sensitization. Nature neuroscience 12, 1069–1073 (2009).
15. Santone, K. S., Oakes, S. G., Taylor, S. R. & Powis, G. Anthracycline-induced inhibition of a calcium action potential in differentiated human myeloblastoma cells. Cancer research 46, 2659–2664 (1986).
16. Cenci, M. A., Whishaw, I. Q. & Schiffert, T. Animal models of neurological deficits: how relevant is the rat? Nature reviews. Neuroscience 3, 574–579 (2002).
17. Bezard, E., Brotchie, J. M. & Gross, C. E. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nature Rev. Neurosci. 2, 577–588 (2001).
18. Jenner, P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature reviews. Neuroscience 9, 665–677 (2008).
19. Phelix, C. F., Lapositis, Z. & Paull, W. K. Monoamine innervation of bed nucleus of stria terminalis: an electron microscopic investigation. Brain research bulletin 28, 949–965 (1992).
20. Freedman, I. J. & Cassell, M. D. Distribution of dopaminergic fibers in the central division of the extended amygdala of the rat. Brain research 633, 243–252 (1994).
21. Hassel, R. H. & Shammah-Lagnado, S. J. Origin of the dopaminergic innervation of the central extended amygdala and accumbens shell: a combined retrograde tracing and immunohistochemical study in the rat. The Journal of comparative neurology 454, 15–33 (2002).
22. Meloni, E. G., Gerety, L. P., Knoll, A. T., Cohen, B. M. & Carlezon, W. A. Jr. Behavioral and anatomical interactions between dopamine and corticotropin-releasing factor in the rat. The Journal of neuroscience 26, 3853–3863 (2006).
23. Kim, S. Y. et al. Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 496, 219–223 (2013).
24. Dong, H., Petrovich, G. D. & Swanson, L. W. Organization of projections from the juxtapacapsular nucleus of the BST: a PHAL study in the rat. Brain research 859, 1–14 (2000).
25. Fudge, J. L. & Haber, S. N. Bed nucleus of the stria terminalis and extended amygdala inputs to dopamine subpopulations in primates. *Neuroscience* 104, 807–827 (2001).

26. Reyv, D. *et al.* Cellular and behavioral outcomes of dorsal striatonsigral neuron ablation: new insights into striatal functions. *Neuropsychopharmacology* 39, 2662–2672 (2014).

27. Daniel, S. E. & Rainnie, D. G. Stress Modulation of Opposing Circuits in the Bed Nucleus of the Stria Terminalis. *Neuropsychopharmacology* 41, 103–125 (2016).

28. Rouillon, C., Abraini, J. H. & David, H. N. Prefrontal cortex and basolateral amygdala modulation of dopamine-mediated locomotion in the nucleus accumbens core. *Exp Neurol* 212, 213–217 (2008).

29. Aubert, I. *et al.* Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. *Annals of neurology* 57, 17–26 (2005).

30. Berthet, A. *et al.* L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. *The Journal of neuroscience* 32, 681–691 (2012).

31. Berthet, A. *et al.* Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. *The Journal of neuroscience* 29, 4829–4835 (2009).

32. Picconi, B. *et al.* Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. *Nature neuroscience* 6, 501–506 (2003).

33. Santini, E. *et al.* Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism. *The Journal of biological chemistry* 287, 27806–27812 (2012).

34. Santini, E. *et al.* Critical involvement of COMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. *The Journal of biological chemistry* 21, 6959–7005 (2007).

35. Feyder, M., Bonito-Oliva, A. & Finone, G. L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopa D1 Receptor-Mediated Transmission. *Frontiers in behavioral neuroscience* 5, 71, doi:10.3389/fnbeh.2011.00071 (2011).

36. Schuster, S. *et al.* The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson’s disease. *The Journal of neuroscience* 28, 4311–4316 (2008).

37. Reiseger, A. R. *et al.* Nicotine self-administration induces CB1-dependent LTP in the bed nucleus of the stria terminalis. *The Journal of neuroscience* 34, 4285–4292 (2014).

38. Cenci, M. A., Lee, C. S. & Bjorklund, A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamatic acid decarboxylase mRNA. *Eur. J. Neurosci.* 10, 2694–2706 (1998).

39. Lundblad, M. *et al.* Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. *The European journal of neuroscience* 15, 120–132 (2002).

40. Engeln, M. *et al.* Reinforcing properties of Pramipexole in normal and parkinsonian rats. *Neurobiology of disease* 49C, 79–86 (2012).

41. Chowdhury, R. *et al.* Dopamine restores reward prediction errors in old age. *Nature neuroscience* 16, 648–653 (2013).

42. Georges, F. & Aston-Jones, G. Activation of ventral tegmental area cells by the bed nucleus of the stria terminalis: a novel excitatory amino acid input to midbrain dopamine neurons. *The Journal of neuroscience* 22, 5173–5187 (2002).

43. McDonald, A. J., Shammah-Lagnado, S. J., Shi, C. & Davis, M. Cortical afferents to the extended amygdala. *Ann. N. Y. Acad. Sci. 877, 309–338 (1999).

44. Kirovu, G. J. Placing the parventricular nucleus of the thalamus within the brain circuits that control behavior. *Neurosci Biobehav Rev* 56, 315–329 (2015).

**Acknowledgements**

This work was supported by a grant and a prize from Fondation de France (E.B.) and LABEX BRAIN ANR-10-LABX-43. M.F.B. is the recipient of an MESR grant. M.B. is the recipient of a France Parkinson fellowship. The University of Bordeaux and the Centre National de la Recherche Scientifique provided infrastructural support. E.B. has equity stake in Motac holding Ltd and receives consultancy payments from Motac Neurosciences Ltd. Current grant support includes Agence Nationale de la Recherche (E.B.), China Science Fund (E.B.), MJFF (E.B.), France Parkinson (E.B.), Fondation de France (E.B., P.O.F.), Medical Research Council (E.B.) and Parkinson Society Canada (E.F.D.).

**Author Contributions**

E.B., F.G., E.C.D. and P.O.F. designed research; M.F.B., C.G., E.D., Q.L. and M.B. performed research. M.F.B., C.G., F.G. and E.B. analyzed data. M.F.B., F.G. and E.B. wrote the paper.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017